FRANCE - EdRIP closes EUR 150m fund

The fund will invest up to EUR 15m in 15 to 20 European life science companies across all stages of development. Investments will cover both therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies.

Investors in the fund include La Compagnie Financiere Edmond de Rothchild, La Caisse des Dépots and Amgen. The fund takes over from BioDiversity 2 which closed in 2005 on EUR 80m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• France